01:30 AM EDT, 09/11/2026 (MT Newswires) -- Swedish biopharmaceutical group Alzinova (ALZ.ST) and partner Worldwide Clinical Trials commenced the operational start-up phase of a phase 2 study of Alzheimer's disease vaccine candidate ALZ-101, according to a Thursday release. The companies are setting up study systems and databases, preparing regulatory and ethics submissions, and allocating clinical trial sites following the study's kick-off. The global, randomized, placebo-controlled trial will enroll 120 participants, with recruitment expected to begin around the turn of 2026/2027. The study's primary endpoint is the change in cognitive function after 52 weeks of treatment, measured using the Alzheimer's Disease Composite Score, or ADCOMS.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.